The Correlated Analysis Of Hyperhomocysteinemia And Drug Therapy Of Parkinson’s Disease

Objective: Parkinson’s disease （PD）is a common degenerative diseases ofnervous system among older persons, the main performance of the disease is movementdisorders.The incidence of it only next to Alzheimer’s Disease in degenerativediseases.With the change of age and the aging of population, The incidence ofParkinson’s disease increased significantly.At present，the correct diagnosis rate wassignificantly elevated.But in the treatment of Parkinson’s disease，the selection oftherapeutic method is not completely correct.At present in the treatment of Parkinson’s disease,，there are still oral medicationfirstly.Levodopa as a drug of replacement therapy of dopamine for the treatment ofpatients with parkinson’s disease. After that, dopamine agonists、 catechol-O-methyltransferase (COMT) inhibitors、MAO-B inhibitors、Anticholinergic agents、Amantadine Gradually by application for the treatment. These drug applicationobviously improving the quality of life of the patients with Parkinson’s disease,but Dueto long-term application also brought the concurrent problems should not be neglected.Levodopa can lead obviously hyperhomocysteine,This phenomenon was found asearly as in1995by Allain, but until1999when muller found again it cause moreattention of researchers. Miller’s study found that levodopa therapy in patients of plasmahomocysteine higher level than with non levodopa treatment. In20cases of Japanesepatients with Parkinson disease study, Yasui found that plasma homocysteine levelswere significantly elevated when levodopa therapy in patients than untreatment. But fordifferent treatment of Parkinson’s disease,whether there exists difference in thepatient’s plasma homocysteine level,there are fewer studys.In order to explore theinfluencing factors and the change in the crowd in different，and more the relationshipbetween the pplasma homocysteine level and Levodopa preparations, The experimentbased on untreated and given different treatment methods to Parkinson’s disease patient’s plasma homocysteine level observation.Further to provide a betterpreferences of treatment for Parkinson’s disease.Methods: Select patients with Parkinson’s disease in the First Affiliated Hospitalof Dalian Medical University Department of Neurology from August2009to December2011.In accordance with the2006Royal Physician Association (UK-PDS) Parkinsondisease diagnosis and treatment guidelines for clinical diagnosed.50Healthy peoplecontrol group,210PD patients,record the clinical date. Hoehn-Yahr staging for patients,210PD patients were divided into4different ways in the treatment（0，untreatmentgroups,1,no L-dopa,2onlyL-dopa,3, L-dopa and/or other drugs）, using circularenzymatic method for the measure of the morning plasma homocysteinelevel.Application of SPSS17.0software to analyze the data.Results:1. In the treatment group,only group2HCY level (18.11±9.96) higherthan the control group (11.16±2.87), The difference was statistically significant(P=0.036<0.05),No difference in the other treatment groups compared with the controlgroup.(group0P=0.534>0.05,group1P=0.244>0.05,group3P=0.27>0.05).2. In different treatment groups, group2HCY level (18.11±9.96) higher thangroup0(11.16±2.87), The difference was statistically significant(P=0.00<0.05).While the other treatment group,group0, group1, between the3groups (P=0.205,0.182,0.818>0.05) were not statistically significant differences.3. In the same sex group,between group0(M15.39±6.45,F11.42±4.19) and group2(M22.34±11.81，F13.89±5.12)there was significant difference of HCY level(M0.004，F0.041), and in the same treatment group,the male group higher than the femalegroup. Two groups in gender composition no difference (P=0.324>0.05).4. When the same gender group HY staging were greater than the2period,betweengroup0(M11.3±6.72，F11.16±2.94) and group2（men group230.38±20.18，Femalegroup216.33±5.49）there was significant difference of HCY level.(M，P=0.003、F，P=0.02)5. When the same gender group HY staging were greater than the2period,betweengroup3（men group316.22±3.34，Female group312.66±4.4） and group2（mengroup230.38±20.18，Female group216.33±5.49）there was significant difference ofHCY level(M0.015、F0.043). Two groups in gender composition no difference.Conclusion:1.when give a separate dopaminergic agents for the treatment ofParkinson’s disease,the plasma homocysteine levels is higher than the control group,Other methods of treatment on plasma homocysteine levels have not obvious difference. 2.when the group give a separate dopaminergic agents for the treatment ofparkinson’s disease, the plasma homocysteine levels is higher than the untreatedgroup,and more, men’s is higher than women’s.,especially when H-Y stage is greaterthan the2period.